Retrospective Study to Assess Real-Life Use of The Long Acting GnRH Agonist as Prostate Cancer Treatment
Retrospective, Non-interventional Study Assessing the Real-Life Use of The Long- Acting Gonadotropin-releasing Hormone Agonist as A Treatment for Locally Advanced or Meta-static Prostate Cancer in Hong Kong.
1 other identifier
observational
237
1 country
1
Brief Summary
It is a retrospective review of the electronic medical record of patients on long-acting triptorelin in Hong Kong.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 4, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
January 4, 2024
CompletedFirst Submitted
Initial submission to the registry
January 11, 2024
CompletedFirst Posted
Study publicly available on registry
January 22, 2024
CompletedJanuary 23, 2024
January 1, 2024
9 months
January 11, 2024
January 21, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
The usage pattern of the long-acting Gonadotropin-releasing Hormone Agonist agonist triptorelin in real-life clinical practice
The duration and type of GnRH agonist
6 months
Secondary Outcomes (1)
The effectiveness of the long-acting Gonadotropin-releasing Hormone Agonist agonist triptorelin in inducing and maintaining castration
6 months
Eligibility Criteria
High risk prostate cancer patient of Chinese heritage from Prince of Wales Hospital since 1 Sept 2018.
You may qualify if:
- Patients of Chinese heritage
- Prostate cancer patients with the following disease status:
- High-risk prostate cancer having hormonal therapy as neoadjuvant / adjuvant treatment for prostatectomy or radiotherapy; or
- Advanced / metastatic prostate cancer treated with long-term hormonal therapy; or
- After primary therapy (surgery or radiotherapy) with biochemical recurrence; or
- Castration-resistant prostate cancer status
- Received at least one dose of 6-month Gonadotropin-releasing Hormone Agonist triptorelin formulation
- Having at least 6 months of follow-up after administration of the 3-month to 6-month Gonadotropin-releasing Hormone Agonist triptorelin
You may not qualify if:
- Nil
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Chinese University of Hong Konglead
- Ipsencollaborator
Study Sites (1)
Prince of Wales Hospital
Shatin, Hong Kong
Related Publications (2)
Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 Apr;10(2):63-89. doi: 10.14740/wjon1191. Epub 2019 Apr 20.
PMID: 31068988BACKGROUNDWeckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol. 2004 Sep;46(3):279-83; discussion 283-4. doi: 10.1016/j.eururo.2004.05.006.
PMID: 15306097BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Chi Fai NG, MD
Chinese University of Hong Kong
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professer
Study Record Dates
First Submitted
January 11, 2024
First Posted
January 22, 2024
Study Start
April 1, 2023
Primary Completion
January 4, 2024
Study Completion
January 4, 2024
Last Updated
January 23, 2024
Record last verified: 2024-01
Data Sharing
- IPD Sharing
- Will not share